Bessemer Group’s AbCellera Biologics ABCL Stock Holding History

Bessemer Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-224,102	Closed	-$2.22M	–	1841
2022 Q3	$2.22M	Buy	+224,102	New	+$2.46M	0.01%	427

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bessemer Group's ABCL Position: Q4 2022 in Review

Bessemer Group sold out of AbCellera Biologics (ABCL) in Q4 2022, closing a stake of 224,102 shares — an estimated $2.22M sold.

Bessemer Group first reported a position in ABCL in Q3 2022 and held it in 1 quarter. The position peaked at $2.22M in Q3 2022. 203 funds tracked by Wall St. Rank hold ABCL as of Q4 2022.

Bessemer Group reported no remaining AbCellera Biologics position as of Q4 2022 after selling out during the quarter.
Bessemer Group sold 224,102 AbCellera Biologics shares in Q4 2022, an estimated $2.22M.
Bessemer Group first reported a position in AbCellera Biologics in Q3 2022 and held it in 1 quarter.
Bessemer Group's AbCellera Biologics position peaked at $2.22M in Q3 2022.
203 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2022.

Based on Bessemer Group's 13F filing for Q4 2022, filed 13 Feb 2023.